VS-7375 (GFH375): An oral, selective KRAS G12D dual ON/OFF inhibitor with potent anti-tumor activity as a single agent and in combination... · CBA Frontier Insights

返回会议原文

CrozrX· @CrozrX · X·2026-04-20 21:10· 2026-04-20评分60

正文 · 机器翻译

VS-7375 (GFH375)：一种口服、选择性的 KRAS G12D 双重 ON/OFF 抑制剂，作为单药及与其他药物联合使用时均具有强大的抗肿瘤活性。

这个三联方案（VS-7375 defactinib 和 avutometinib）正在进行吗
@DavidHongMD
?

@AACR

@ElizSMcKenna

@KRASKickers
#AACR26

热度 0 · 0 赞 · 0 回复 · 0 转发

会议摘要

6386按药名 avutometinib 对上

Small bowel obstruction and short bowel syndrome may impair the efficacy of Avutometinib and Defactinib in recurrent low grade serous ovarian cancer: A case report.

Sarah Ottum, Luca Palmieri, Victoria Ettorre, Tobias Hartwich, Cem Demirkiran, Namrata Sethi, Stefania Bellone, Alessandro D. Santin

读摘要原文 →

LB183按代号 VS-7375 对上

Strong durable tumor regressions with the KRASG12D ON/OFF inhibitor VS-7375 in combination with PRMT5 inhibition in MTAP-deleted/KRASG12D-mutant pancreatic cancer

Ryan D. Mouery, Kristina Drizyte-Miller, Clint A. Stalnecker, Adrienne D. Cox, Silvia Coma, Jonathan A. Pachter, Channing J. Der

读摘要原文 →

LB197按代号 VS-7375 对上

VS-7375, a non-covalent dual ON/OFF KRASG12D inhibitor, displays superior activity to ON-only KRASG12D inhibitors in preclinical models of pancreatic cancer

Brandon L. Mouery, Clint A. Stalnecker, Adrienne D. Cox, Silvia Coma, Jonathan A. Pachter, Channing J. Der

读摘要原文 →

7100NCT06500676 NCT07020221按代号 VS-7375 对上

VS-7375: An oral, selective KRAS G12D dual ON/OFF inhibitor with potent anti-tumor activity as a single agent and in combination with other agents

Silvia Coma, Ian Smith, Cristina Caffarra Malvezzi, Clint A. Stalnecker, Emilia Berardelli, Enrico Patrucco, Fusheng Zhou, Channing Der, Chiara Ambrogio, David G. DeNardo, Jonathan A. Pachter

读摘要原文 →

来源：CrozrX · x.com